240 results
6-K
EX-99.1
BLRX
BioLineRx Ltd.
19 Aug 24
Notice of Annual General Meeting of Shareholders
4:30pm
a personal identifying number, an access code and additional information regarding this Meeting from the member of the TASE and after carrying out … ; and (iii) by voting electronically via the ISA Electronic Voting System, after receiving a personal identifying number, an access code and additional
6-K
EX-3
BLRX
BioLineRx Ltd.
15 Aug 24
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate
7:06am
for our therapeutic candidates, and the timing of other regulatory filings and approvals;
whether access to APHEXDA is achieved in a commercially viable … ;
estimates of our expenses, future revenues, capital requirements and our need for and ability to access sufficient additional financing, including
6-K
EX-1
BLRX
BioLineRx Ltd.
15 Aug 24
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate
7:06am
Conference Call and Webcast Information
To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally … of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner
6-K
EX-1
BLRX
BioLineRx Ltd.
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA … property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient
6-K
EX-99.3
BLRX
BioLineRx Ltd.
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
for our therapeutic candidates, and the timing of other regulatory filings and approvals;
whether access to APHEXDA is achieved in a commercially viable … ;
estimates of our expenses, future revenues, capital requirements and our need for and ability to access sufficient additional financing, including
6-K
EX-99.1
41y07cvczavksrpb9
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
6-K
EX-99
26rt9n jxivbk22b8tf5
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
6-K
EX-99
oxz1cg34
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
6-K
EX-99
s5l8q9wapksjoj0
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
drcqw3r4oellnc4z
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
m93hpi hfbs
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-10.1
t7zi3u1
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
6-K
EX-99.1
dyqpwz8
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
d6iw79xed7rdi
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
0ubiyl m9h3
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
bqfrp0uy
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
bhtsmcyk sfpxux
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
eq6xnekj
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am